美国食品药品监督管理局（FDA）已批准Leqembi皮下注射剂型用于治疗阿尔茨海默病的新起始给药方案。这一监管决定为患者提供了更便捷的治疗选择，有望改善用药依从性。
Leqembi由渤健公司（Biogen）与合作伙伴共同开发，此次新方案的获批标志着其在阿尔茨海默病治疗领域取得了又一重要进展。皮下注射剂型相较于静脉输注，能简化给药流程，为患者和护理人员带来便利。
新起始剂量方案的确定基于临床数据，旨在优化治疗效果并管理潜在风险。随着全球阿尔茨海默病患者数量持续增长，此类创新疗法的推进对满足未竟医疗需求具有重要意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.